Director’s Major Stock Sale Shakes Up Kymera Therapeutics

New insider activity at Kymera Therapeutics ( (KYMR) ) has taken place on December 12, 2025.Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential Director Bruce Booth has made a significant move by selling 236,588 shares of Kymera Therapeutics stock, amounting to a substantial $21,699,043. Recent Updates on KYMR stock Kymera Therapeutics has seen a significant increase in its stock price targets from several analysts following positive developments in its clinical trials and regulatory progress. The company’s KT-621, an oral STAT6 degrader, received Fast Track designation from the FDA for treating moderate to severe atopic dermatitis, which has been a key factor in the raised price targets. Analysts from Stephens, Mizuho, and JPMorgan have all increased their price targets, citing the compelling efficacy and safety profile demonstrated in the Phase 1b BroADen trial, which de-risks the program and increases the probability of success in future trials for atopic dermatitis and asthma. These developments, along with a major stock offering, are expected to enhance Kymera’s market position and support its operations into the future. Spark’s Take on KYMR Stock According to Spark, TipRanks’ AI Analyst, KYMR is a Neutral. Kymera Therapeutics’ overall stock score is primarily impacted by its poor financial performance, which is a significant concern. However, strong technical indicators and positive corporate events provide some optimism. The earnings call also suggests strategic progress, but high expenses and valuation concerns remain. To see Spark’s full report on KYMR stock, click here. More about Kymera Therapeutics YTD Price Performance: 114.75% Average Trading Volume: 966,077 Technical Sentiment Signal: Buy Current Market Cap: $6.47B